Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

ABSTRACT:

Purpose

PD-L1 is the main ligand for the immune inhibitory receptor PD-1. This ligand is frequently expressed by melanoma cells. In this study, we investigated whether PD-L1 expression is controlled by melanoma driver mutations and modified by oncogenic signaling inhibition.

Experimental design

Expression of PD-L1 was investigated in a panel of 51 melanoma cell lines containing different oncogenic mutations, including cell lines with innate and acquired resistance to BRAF inhibitors (BRAFi). The effects of targeted therapy drugs on expression of PD-L1 by melanoma cells were investigated.

Results

No association was found between the level of PD-L1 expression and mutations in BRAF, NRAS, PTEN, or amplification of AKT. Resistance to vemurafenib due to the activation of a

SUBMITTER: Atefi M 

PROVIDER: S-EPMC4079734 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature